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Evidence that renal prostaglandins are involved in renal water metabo-
lism in cirrhosis. Plasma antidiuretic hormone (ADH) and urinary pros-
taglandin E2 excretion (UPGE,V) were measured in basal conditions,
after water restriction, and after water-loading in 10 normal subjects
(free water clearance after the water load, CH2O, 9.6 0.8 ml/min) and
in 27 patients with cirrhosis and ascites (13 with a positive CH2O: 3.6
0.5; 14 with a negative CH20: —0.37 0.007). Plasma ADH and
UPGE2V were significantly increased in patients with a positive CH2O
as compared with normal subjects. Patients with a negative CH2O
showed a significantly higher plasma ADH and a lower UPGE2V and
GFR than did normal subjects and patients with the positive Cu2o. In
18 additional subjects (6 normal and 12 with cirrhosis, ascites, and a
positive CH20) submitted to a sustained water overload, the iv. admin-
istration of 450 mg of lysine acetylsalicylate (LAS) induced a marked
reduction of UPGE2V, but it had no effect on plasma ADH. LAS did
not alter GFR and C2o in normal subjects; however, it reduced CH2O
in all the 12 patients (from 5.1 0.4 to 0.6 0.3) and the GFR in only
6 of these patients. These results suggest (a) that renal PGE2 plays an
important role in the maintenance of water excretion in cirrhosis with
ascites, and (b) that impaired ability to dilute the urine in cirrhosis may
be a consequence of the simultaneous occurrence of impaired renal he-
modynamics, nonostomic hypersecretion of ADH, and reduced renal
production of PGE2.
Preuve du role des prostaglandines rénales dans le métabolisme hy-
drique renal au cours de Ia cirrhose. L'hormone antidiurétique (ADH)
plasmatique et l'excrétion urinaire de prostaglandine E2 (UPGE2V) ont
Cté mesurées dans des conditions basales et après restriction hydrique
et surcharge en eau chez 10 sujets normaux (clearance de l'eau libre
apres Ia charge hydrique, C H20, 9,6 0,8 mI/mm) et chez 27 cirrho-
tiques avec ascite (13 avec Ci2o positive, 3,6 0,5; 14 avec CH20
negative, —0,37 0,007). L'ADH et UPGE2V étaient significative-
ment augmentées chez les malades ayant une CH2O positive par rap-
port aux sujets normaux. Les cirrhotiques ayant une CH20 negative
présentaient une ADH significativement plus élevée et UPGE2V et GFR
moindres que les sujets normaux et les malades ayant une CH2O posi-
tive. Chez 18 sujets supplémentaires (6 normaux et 12 cirrhotiques
avec une ascite et CH2O positive) soumis a une surcharge hydrique main-
tenue, l'administration iv. de 450 mg de lysine acetylsalicylate (LAS)
a induit une reduction marquee de UPGE2 mais a été sans effet sur
l'ADH. LAS n'a altéré ni GFR ni CH2O chez les sujets normaux. Ce-
pendant, il a réduit CH2O chez les 12 cirrhotiques étudiés (de 5,1 0,4
a 0,6 0,3) mais GFR chez seulement six de ces malades. Ces
résultats suggèrent que (a) Ia PGE2 rénale joue on role important dans
le maintien de l'excrëtion hydrique au cours de Ia cirrhose avec ascite,
(b) l'altération de Ia capacité de diluer les urines au coors de Ia cir-
rhose pourrait ëtre one consequence de la survenue simultanCe
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d'altérations de I'hemodynamique rénale, d'une hypersecretion non
osmotique d'ADH et dune reduction de Ia production rénale de PGE2.
A moderate impairment of the renal ability to excrete free
water, detectable only after a water load, is common in cirrho-
sis with ascites [1]. In many patients however, this disorder is
so marked that they are unable to elaborate a positive free wa-
ter clearance after a water load. These patients usually have
dilutional hyponatremia and hypoosmolality [21. The mecha-
nism of the impaired water excretion in cirrhosis is not well es-
tablished. Several studies in experimental animals and in pa-
tients suggest that it may involve both a reduced delivery of
fluid to the diluting segment of the nephron that is secondary
to an excessive proximal sodium reabsorption, and a nonos-
motic hypersecretion of antidiuretic hormone [3—8]. The con-
tributory role of other factors known to influence renal water
metabolism, such as renal prostaglandin E2 (PGE2) [9], has
never been investigated in cirrhosis.
In the present study, the glomerular filtration rate (GFR), the
plasma concentration of antidiuretic hormone (ADH), and the
urinary excretion of PGE2 (UPGE2V) were measured in normal
subjects and in patients with cirrhosis and ascites and were re-
lated with their renal ability to excrete free water. Moreover,
the effect of prostaglandin inhibition on these processes was in-
vestigated in another group of normal volunteers and patients
with ascites. The aim of the study was to investigate the
mechanisms of the renal impairment of water excretion in cir-
rhosis and, particularly, to assess the potential role of renal
PGE2 in the renal metabolism of water in these patients.
Methods
The present study had two protocols, which were approved
by the Investigation and Ethics Committee of the Hospital
ClInico y Provincial of Barcelona (December 1980). Informed
consent was obtained from each subject studied.
Protocol 1. The aim of protocol I was to investigate the re-
lationship between the impairment of water excretion in cir-
rhosis and the plasma level of ADH, UPGE2V, and renal
hemodynamics.
The study was performed in 10 healthy subjects and in 27 pa-
tients with cirrhosis who were admitted to our unit for the
treatment of an episode of ascites. In 20 patients, the diagnosis
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of cirrhosis was based on liver biopsy findings. In the remain-
ing 7 patients, it was based on clinical and laboratory data. The
etiology of cirrhosis was alcoholism in 15 patients, unknown in
10, and hepatitis B surface antigen associated in 2. By exclu-
sion criteria, no patient had arterial hypertension, clinical data
suggesting respiratory, cardiac or renal disease, infection, hep-
atoma, gastrointestinal hemorrhage, hepatic encephalopathy,
or had been treated with potentially nephrotoxic or non-steroi-
dal antiinflammatory drugs before admission to the hospital.
Moreover, patients with severe functional renal failure and
marked oliguria were not studied either.
After admission in the hospital, patients were given a diet
containing 50 mmoles of sodium daily, and they did not re-
ceive diuretics or any other drug for 6 days. Water intake was
not restricted. The normal subjects were also studied after 6
days on a 50-mmole sodium diet. In the morning of day 7, af-
ter overnight fasting from food but not from liquids and follow-
ing 2 hours of bed rest, they were catheterized through an an-
tecubital vein. Thirty minutes later, blood samples were taken
to measure plasma renin activity (PRA), plasma levels of nor-
epinephrine (NE) and ADH (arginine-vasopressin), blood urea
nitrogen (BUN), plasma osmolality, and plasma concentration
of creatinine, sodium, and potassium. Samples for PRA, NE,
and ADH were collected under ice in potassium EDTA, EGTA
plus glutation, and lithium heparin tubes, respectively. They
were centrifuged at 4° C, and the plasma was frozen at —30° C
until assayed. Immediately afterwards, an 8-hour urine volume
(from 9 A.M. to 5 p.M.) was carefully collected in a container
with tris-HCL buffer (pH, 7.4) and kept at 4° C. Aliquots of this
urine were frozen at — 30° C until assayed for urinary concen-
tration of PGE2. The urine osmolality and the urinary concen-
tration of sodium and potassium were also measured. In the
morning of day 8, after 16 hours of complete fluid restriction,
a 2-hour urine volume was collected to measure urine osmo-
lality and urinary concentration of PGE2, and a blood sample
was taken to determine the plasma concentration of ADH and
osmolality. Immediately afterwards, an i.v. water overload (5%
glucose) of 20 ml/kg of body wt was given during 45 minutes.
Fifteen minutes later, the urine was collected (usually by spon-
taneous voiding) during four periods of 30 minutes. In the
middle of each period, a blood sample was taken. During all the
study, the initial water overload was maintained by infusing a
volume of 5% glucose equal to the urine volume. The follow-
ing parameters were determined on each period: urine volume,
plasma and urine osmolality, osmolar clearance, free water
clearance, and UPGE2V. Moreover, a blood sample to measure
the plasma concentration of ADH was taken during the fourth
30-minute urine collection period. Simultaneously with these
determinations, the GFR was measured by the inulin clear-
ance method described in the following sections.
Protocol 2. The aim of protocol 2 was to investigate the ef-
fect of prostaglandin inhibition on free water clearance, GFR,
UPGE2V, and plasma concentration of ADH in 6 normal sub-
jects and in 12 cirrhotic patients with ascites who had a posi-
tive free water clearance after a water load. None of these sub-
jects were included in protocol 1. Patients with renal failure
were not studied because prostaglandin inhibition could de-
teriorate renal function even more.
The study was made 6 days after initiation of a 50-mmole so-
dium diet and discontinuance of diuretics. A priming dose of
inulin (50 mg/kg of body wt) was given i.v., followed by a con-
stant infusion (2 ml/min) throughout the study of a saline so-
lution of this substance (1.25 g/dl). After an equilibration pe-
riod of 90 minutes, the urine was collected (in cirrhotic pa-
tients, it was collected usually through an indwelling bladder
catheter) in 30-minute periods, in the middle of which a blood
sample was taken. During the first 45 minutes of the equilibra-
tion period, an i.v. water overload (5% glucose, 20 ml/kg of
body wt) was also given. This water overload was kept con-
stant throughout the study by infusing a volume of 5% glucose
equal to the urine volume. After two 30-minute urine collec-
tion periods (control periods), an i.v. injection of 450 mg of ly-
sine acetylsalicylate (equivalent to 250 mg of acetylsalicylic
acid) was given, followed 10 minutes later by three further 30-
minute urine collection periods. The urine volume of each pe-
riod was measured, and aliquots were separated to determine
inulin, osmolality, and PGE2 concentration. Blood samples
were centrifuged, and the plasma analyzed to determine osmo-
lality and inulin concentration. Moreover, the plasma levels of
ADH were measured in samples obtained in the second con-
trol period and in the third period after the administration of
lysine acetylsalicylate.
Measurements. The plasma concentration of ADH was mea-
sured by radioimmunoassay following a method previously de-
scribed [10]. The hormone was extracted from plasma with
cold 98% ethanol, and the extracts were incubated in a non-
equilibrium system with a highly specific antibody (Calbio-
chem-Behring Corp., La Jolla, CA) and '251-labeled arginine-
vasopressin of high specific activity (greater than 1500
kCi/mole). The buffer used for radioimmunoassay was barbital
(20 mmole/liter; pH, 8.6), containing per liter: 0.14 mole of so-
dium chloride, 0.01 mole of EDTA, and 10 ml of normal rabbit
serum. Incubation times were 29 hours for the first incubation
and 24 hours for the second incubation. These incubation times
were selected after kinetic studies. The temperature of incu-
bations was 4° C. The bound-to-free fractions were separated
by charcoal-dextran. The coefficient of variation was 11% for
intraassay and 14% for interassay determinations. The percent-
age of recovery of ADH in this assay ranged between 81% and
90%, and the smallest amount of ADH that could be detected
was 0.31 pg per tube, which corresponds to 0.5 pg/mI.
PRA was estimated by the radioimmunoassay (Clinical As-
says, Cambridge, MA) of generated angiotensin I (Al) after one
hour's incubation at a pH of 7.4 and at 30° C, in conditions in-
hibiting further conversion of AT. The coefficient of variation
within one assay was 8% and 12% for interassay determina-
tions. The percentage of recovery of AT in this assay ranged be-
tween 80% and 97%.
Plasma NE was measured by the radioenzymatic assay of
Peuler and Johnson [11] (Upjohn Diagnostics, Kalamazoo,
MI). Norepinephrine was converted to labeled normetaneph-
rifle by catechol-o -methyltransferase, using s-adenosyl methio-
nine (3H-methyl) as labeled methyl group donor. Normetaneph-
rifle was then isolated on thin-layer chromatography, scrapped
and counted in a liquid scintillator. The coefficient
of variation was 4% for intraassay and 10% for interassay
determinations.
Urinary PGE2 was measured by radioimmunoassay [12].,
Prostaglandins were extracted with ethyl acetate, isolated on a
silicic acid chromatographic column, and eluted with toluen-
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Fig. 1. Individual values of free water clearance after water overload.
Group 1 is normal subjects; group 2, cirrhotic patients with positive
free water clearance; and group 3, cirrhotic patients with negative free
water clearance. Values represent the arithmetic mean of the four free
water clearances determined on each subject.
ethyl-acetate-methanol (70-30-5). The PGE2 fraction was an-
alyzed by an equilibrium radioimmunoassay using a highly spe-
cific antibody (Institut Pasteur, Paris). The bound-to-free frac-
tions were separated by protein A obtained from a brute cul-
ture of Staphylococcus aureus (Staffinoc, Kabi, Sweden). The
coefficient of variation within one assay was 8% and 14% for
interassay determinations. The percentage of recovery of PGE2
in this assay ranged between 90 and 110%.
Inulin was analyzed by the method of Heyrovsky l3].
Osmolalities were determined by depression of freezing point
(Advanced Instruments, Needham Heights, MA) and free wa-
ter clearance was calculated by the difference between urine
flow rate and osmolar clearance. Serum electrolytes were mea-
sured by flame photometry and BUN and serum creatinine
with a Technicon autoanalyzer (Technicon Instruments Corp.,
Tarryton, NY).
Statistical analysis. The statistical analyses of the results
were made using the Kolmogorov's goodness-of-fit test for a
normal distribution; Kruskal Wallis analysis of variance by
ranks; nonparametric tests of Mann-Whitney; paired and
unpaired Student's t test; Wilcoxon test; and two-variable lin-
ear regression. Results are presented as the means SEM.
Protocol 1
Results
Classification of the subjects. As indicated in Fig. 1 , all but
one of the patients with ascites showed a lower renal ability to
excrete water, estimated by the free water clearance after wa-
ter loading, than normal subjects. The degree of impairment of
water excretion, however, varied greatly from one patient to
another, and whereas some of them showed a relatively high
free water clearance, others were unable to excrete free water
Group 2 Group 3 P
Age, years 53.8 2.6 52.2 2.4 NS
Sex, no. male/no, female 9/4 8/6 NS
Etiology of cirrhosis,
no, alcoholic/no, nonalcoholic 7/6 8/6 NS
Ascites volume, grade 2/grade 3 9/4 7/7 NS
Peripheral edema, no. patients 9 11 NS
Mean arterial pressure, mm Hg 84.2 2.4 81.4 2.9 NS
Serum bilirubin, moles/liter 60.7 14.2 57.1 10.7 NS
Prothrombin time,
sec prolonged 2.4 0.5 1.4 0.3 NS
Plasma albumin, moles/liter 398 17.3 382 27.5 NS
after the water overload (negative free water clearance). Based
on the renal ability to excrete water, subjects were classified
into three groups (Fig. 1): Group 1 was the 10 normal subjects
(free water clearance, 9.6 0.8 mi/mm; urine osmolality after
the water overload, 74 6 mOsm/kg). Group 2 was the 13 pa-
tients who had a positive free water clearance after the water
load (free water clearance, 3.6 0.5 ml/min; urine osmolality
after the water load, 101 10 mOsm/kg). Group 3 was the 14
patients who had a negative free water clearance after the wa-
ter load (free water clearance, —0.37 0.07 ml/min; urine
osmolality after the water load, 468 38 mOsm/kg).
Table I shows that the two groups of patients with cirrhosis
were not significantly different with respect to the clinical data
and standard liver function tests.
Renal function and baseline values of PRA, plasma NE and
ADH, and UPGE2V. Table 2 shows the renal function and the
baseline levels of PRA, NE, ADH, and UPGE2V in the three
groups of subjects studied. Figure 2 shows the individual val-
ues of GFR, ADH, and UPGE2V.
There were no significant differences between patients of
group 2 and the normal subjects with respect to inulin clear-
ance, BUN, and plasma creatinine concentration. The GFR
was within the normal limits in 8 patients of group 2 and only
slightly reduced in the remaining 5. In contrast, most patients
of group 3 had a marked impairment of GFR. Both groups of
patients had a significantly lower plasma sodium concentra-
tion, plasma osmolality, urine volume, and sodium excretion,
and a significantly higher PRA and plasma concentration of NE
and ADH than did normal subjects. GFR, plasma sodium con-
centration and urinary sodium excretion were significantly re-
duced, and BUN, serum creatinine concentration, PRA, and
plasma NE and ADH were significantly increased in patients
of group 3 as compared with patients of group 2. Both groups
2 and 3 were not significantly different with respect to total
plasma osmolality; however, the effective plasma osmolality
(estimated by the equation total plasma osmolality — BUN/2.8)
was significantly lower (P < 0.05) in patients of group 3 (264.7
3.1 mOsm/kg) as compared with patients of group 2 (273.2
1.7). Group 2 showed a significantly higher UPGE2V than
normal subjects. On the contrary, group 3 showed a signifi-
cantly lower UPGE2V than normal subjects and group 2.
In all the patients, free water clearance showed a significant
Table 1. Clinical and laboratory data in the two groups of patients
with cirrhosisa
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in the evaluation of ascites volume, grade 2 indicates moderate
ascites and grade 3 severe ascites. NS = not significant. Where "±"
sign is used, values are the means SEM.
Prostaglandins, ADH, and water metabolism in cirrhosis 75
Table 2. Renal function and baseline levels of plasma renin activity (PRA), plasma concentrations of norepinephrine (NE) and antidiuretic
hormone (ADH), and urinary excretion of prostaglandin E2 (UPGE2V) in the three groups of subjects
Group 1(N = 10)
Group 2(N = 13)
Grou
(N =p 314)
P
1 vs. 2 1 vs. 3 2 vs. 3
BUN, mmoles/liter
Serum creatinine, ,umoles/liter
Inulin clearance, mI/mm
Urine volume, mi/mm
Plasma sodium, mmoles/liter
Plasma osmolality, mOsm/kg
Sodium excretion, ixmoles/min
Urine osmolality, mOsm/kg
PRA, ng/mllhr
Plamsa NE, pg/mI
Plasma ADH, pg/mi
UPGE2V, ng/min
5.7 0.49
88.4 4.4
100 4.4
0.81 0.07
140 0.6
291 3.5
62 13
575 60
1.03 0.15
200 22
2.45 0.16
0.26 0.02
4.2 0.60
97.2 2.6
87 7.5
0.42 0.07
134 0.9
278 1.6
7 1.7
672 45
5 0.87
436 61
2.96 0.16
0.61 0.14
11.7
150
43
0.39
129
277
2
537
12.5
665
4.23
0.12
1.9
17.6
5.9
0.07
1.5
3.8
0.8
31
3.1
81
0.36
0.02
NS
NS
NS
<0.01
<0.001
<0.01
<0.001
NS
<0.01
<0.01
<0.05
<0.05
<0.05
<0.05
<0.001
<0.001
<0.001
<0.05
<0.001
NS
<0.001
<0.001
<0.01
<0.01
<0.001
<0.05
<0.01
NS
<0.01
NS
<0.05
NS
<0.01
<0.05
<0.05
<0.001
a Values are the means SEM.
direct correlation with GFR (r = 0.72; P < 0.001) and baseline
UPGE2V (r 0.69; P < 0.001), and an inverse correlation with
baseline plasma ADH (r =
—0.46; P < 0.05).
Urine volume, plasma and urine osmolality, free water clear-
ance, plasma ADH, and UPGE2V after water restriction and
water loading. Table 3 shows the results obtained after water
restriction and water loading. As has previously been reported
l4], patients with cirrhosis showed an impaired renal ability to
concentrate the urine. Their urine osmolality and free water
clearance after water restriction were significantly (P < 0.001)
lower and higher, respectively (urine osmolality, 561 33
mOsm/kg; free water clearance, —0.40 0.06 mI/mm), than
those measures were in normal subjects (urine osmolality, 851
81 mOsm/kg; free water clearance, —0.95 0.15 ml/min).
The impairment of the renal concentrating ability was particu-
larly marked in group 3 (Table 3).
As shown in Table 3, the water overload produced a similar
reduction of plasma osmolality in the three groups. In normal
subjects, the mean plasma osmolality after water restriction
was 293.9 2.7 mOsm/kg, and it decreased to 286.3 3.1
mOsm/kg (P < 0.001) after water loading. In groups 2 and 3,
the plasma osmolality after water restriction was 282.1 2.7
and 279.2 5.8 mOsm/kg respectively, and they decreased to
275.6 3.1 and 272.7 5.5 mOsm/kg (P <0.001) after water
loading. In spite of this similar change in plasma osmolality,
there were marked differences betwen the three groups with re-
spect to plasma ADFI levels after water loading (Table 3 and
plasma ADH to that of normal subjects (group 1). On the other
hand, plasma ADH decreased significantly in both these groups
after water loading. The percent reduction of plasma ADH lev-
els induced by the water load was, however, significantly lower
(P < 0.001) in group 2 (21%) than in group 1 (63%), in such a
manner that most of group 2 had a plasma concentration of
ADH after water loading similar to that presented by the nor-
mal group in conditions of water restriction (Fig. 3). Group 3
showed a significantly higher plasma ADH after water restric-
tion than normal subjects and group 2. The water overload did
not produce any significant change in ADH in this group.
As in basal conditions, UPGE2V after water restriction and
water loading was significantly increased in group 2 and re-
duced in group 3 as compared to normal (Table 3).
Protocol 2
Effect of lysine acetylsalicylate on GFR, free water clear-
ance, AJJH, and UPGE2V. Results of protocol 2 are presented
in Table 4. In normal subjects and in patients with ascites, ly-
sine acetylsalicylate induced a significant reduction of UPcE2V.
This was associated with a marked and reversible decrease of
GFR in 6 of the 12 patients (group 2b of Table 4). In the re-
maining 6 patients (group 2a of Table 4) and in all the normal
subjects (group 1 of Table 4), lysine acetylsalicylate did not
produce any significant change in GFR.
In normal subjects, the administration of lysine acetylsalic-
ylate was not associated with any change in urine volume and
Fig. 2. Individual values of GFR, plasma
antidiuretic hormone (ADH), and urinary
excretion of prostaglandin E2 (PGE2) obtained
in basal conditions. Group 2 patients (those
with positive free water clearance) showed a
significantly higher ADH and urinary PGE2
excretion than did group I (normal subjects)
(see Table 2). Group 3 patients (those with
negative free water clearance) showed a
significantly higher ADH and lower GFR and
urinary PGE2 excretion than did groups 1 or 2
(see Table 2).
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Fig. 3). After water restriction, group 2 showed a similar free water clearance. In patients, however, this drug induced a
Group 2 Group 3 gesting that renal hemodynamics was also an important factor.
Subsequent studies showing that proximal sodium reabsorp-
tion may be increased in cirrhosis [4, 5] and that free water
clearance after water loading correlates closely with GFR in
these patients [17] confirmed these early investigations. Re-
cently, Bichet et al [6, 7] evaluated the role of ADH in the im-
pairment of water excretion in cirrhosis by measuring the
plasma concentration of ADH, in basal conditions and after
water loading, in patients who were able to excrete water nor-
mally (most of them had no ascites) and in patients with asci-
tes and abnormal water excretion. Both groups of patients
were found to be not significantly different with respect to base-
line ADH. The water overload, however, suppressed ADH to
undetectable levels in patients who excreted water normally,
but not in patients with abnormal water excretion. Although
Bichet et al did not study normal subjects or cirrhotic patients
with renal failure, which are those with greater impairment of
water excretion, their findings strongly suggest that a nonos-
motic stimulation of ADH is another important factor in the ab-
normal water excretion in cirrhosis.
The results of the current study extend those obtained by Bi-
chet et al 16, 7] and support the hypothesis that in cirrhosis with
ascites there is a nonosmotic hypersecretion of ADH that may
be involved in the pathogenesis of the impaired water excre-
tion and dilutional hyponatremia. The following findings are in
keeping with this contention: (1) The plasma concentrations of
ADH in basal conditions and after water loading were signifi-
cantly higher in the two groups of cirrhotic patients studied
than in normal subjects (Figs. 2 and 3). It is important to point
out that the increased ADH levels in patients occurred in the
setting of a reduced plasma osmolality, a potent inhibitory fac-
tor of ADH secretion, which suggests that their plasma ADH
would be even higher if plasma hypoosmolality was not pres-
ent. (2) The administration of a water load that reduced plasma
osmolality in the three groups by approximately 7 mOsm/kg
(Table 3) failed to produce an appropriate suppression of ADH
in two patient groups (Fig. 3), suggesting that hypersecretion
of ADH in these patients was secondary to a nonosmotic
stimulus. (3) In the patients with cirrhosis, there was an in-
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Table 3. Urine volume, plasma and urine osmolality, free water clearance, plasma ADH, and Upor2V after water restriction and water loading
in the three groups of subjectsa
Plasma Urine Urine Free water Plasma
osmolality volume osmolality clearance ADH UPGE2V
mOsm/kg mi/mm mOsm/kg mi/mm pg/mi ng/min
After water restriction
Group 1 293.9 2.7 0.58 0.12 851 81 —0.95 0.15 3.63 0.31 0.18 0.01
Group 2 282.1 2.7 0.43 0.10 665 48 —0.60 0.19 3.56 0.32 0.49 0.12
Group 3 279.2 5.8 0.37 0.05 473 28 —0.23 0.03 4.95 0.44 0.08 0.02
P(l vs. 2) <0.05 NS NS NS NS <0.01
P (1 vs. 3) <0.01 NS <0.001 <0.001 <0.05 <0.05
P (2 vs. 3) NS NS <0.01
After water loading
<0.01 <0.05 <0.001
Group 1 286.3 3.1 11.4 0.96 74 6 9.6 0.8 1.28 0.21 1.65 0.31
Group 2 275.6 3.1 5.3 0.62 101 10 3.6 0.5 2.71 0.25 3.90 0.57
Group 3 272.7 5.5 0.58 0.08 468 38 —0.37 0.07 4.42 0.39 0.28 0.13
P (1 vs. 2) <0.05 <0.001 <0.05 <0.001 <0.01 <0.02
P (1 vs. 3) <0.01 <0.001 <0.001 <0.00! <0.001 <0.001
P (2 vs. 3) NS <0.001 <0.001 <0.001 <0.001 <0.001
Group 1
8r
a Values for plasma osmolality, urine volume and osmolality, free water clearance, and UPGE2V after water loading represent the arithmetic
mean of those obtained in the four 30-minute urine collection periods performed after the water overload.
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Fig. 3. Plasma antidiuretic hormone (ADH) concentration after water
restriction (A) and water loading (B). Group 1 is normal subjects;
group 2, cirrhotic patients with positive free water clearance after the
water overload; and group 3, cirrhotic patients with negative free wa-
ter clearance after the water overload.
A A B A B
marked reduction of both parameters. This occurred regard-
less of whether GFR decreased or not.
In patients, the plasma concentration of ADH was similar
before and after the administration of lysine acetylsalicylate.
Discussion
Since the article of Aldersberg and Fox in 1942 [15] indicat-
ing that patients with cirrhosis and ascites frequently develop
an impaired renal ability to excrete free water, several studies
investigating the pathogenesis of this disorder have been pub-
lished. In 1960 Schedl and Bartter [3] first suggested that a re-
duced distal delivery of fluid secondary to an increased so-
dium reabsorption in the proximal tubule may be an important
mechanism. Two years later, Lancestremere et al [16] found
that most of these patients with impaired GFR were unable to
elaborate hypotonic urine after a water load, whereas this only
occurred in a minority of patients with preserved GFR, sug-
Prostaglandins, ADH, and water metabolism in cirrhosis 77
Table 4. Effect of lysine acetylsalicylate on urinary excretion of prostaglandin E2 (UpGE2V), GFR, free water clearance, and plasma antidiuretic
hormone (ADH) in the 6 normal subjects (group 1) and the 12 patients with ascites (group 2) included in protocol 2"
C1 C2 LAS1 LAS2 LAS3
UPGE2V, ng/min
Group 1 1.62 0.38 1.92 0.42 1.10 0.38& 0.90 0.22 0.86 0.23
Group 2a 3.36 0.94 3.28 1.03 1.70 0.44k 0.31 0.08 0.74 0.27
Group 2b 4.20 1.01 3.30 0.90 0.75 0.20k 0.14 0.05 0.33 0.08
GFR, mi/mm
Group 1 109 12 117 13 124 21 114 19 122 15
Group 2a 100 8 96 9 92 9 104 8 100 12
Group 2b 100 13 95 15 77 15 45 12# 94 26
Free water clearance, mi/mm
Group 1 10.3 1.5 11.9 1.6 11.9 1.8 9.5 1.3 9.8 1.2
Group 2a 4.9 0.4 4.8 0.4 2.7 0.5'' 0.6 0.5'' 0.9 0.7''
Group 2b 5.3 0.7 5.3 0.9 2.8 1.2 0.7 0.4# 0.3 0.2''
Plasma ADH, pg/mi
Groupl — — — — —
Group 2a — 2.94 0.17 — — 2.50 0.48
Group 2b — 3.01 0.45 — — 2.88 0.34
a Cirrhotic patients with ascites are divided in two subgroups: Group 2a includes 6 patients who did not develop a decrease of renal function after
the administration of lysine acetylsalicylate. Group 2b includes the remaining 6 patients who developed renal insufficiency after lysine
acetylsalicylate. C1 and C2 represent the two 30-minute control periods before the administration of lysine acetylsalicylate; LAS1, LAS2, and LAS3
represent the three 30-minute periods after the administration of lysine acetylsalicylate.
b Statistical significance is denoted by the following symbols: p < 0.05; < 0.02; &p < 0.005; < 0.001, with respect to control values.
verse relationship between plasma ADH concentration and
free water clearance. Those with negative free water clearance
(group 3) showed a significantly higher plasma concentration of
ADH in basal conditions (Fig. 2) and after water loading (Fig.
3) than did those with positive free water clearance (group 2),
in spite of their having a significantly lower effective plasma
osmolality.
It is well established that ADH is metabolized by the liver
and kidney, and there are preliminary data indicating that liver
disease may prolong the plasma half-life of this hormone [18].
Therefore, because many patients who are studied have renal
failure in addition to hepatic failure, it could be suggested that
their elevated plasma level of ADH was due to an impaired
metabolic clearance rate rather than to an increased ADH re-
lease. However, this possibility is unlikely. If the underlying
disorder were only a reduced metabolic clearance rate of ADH,
the resulting water retention and hypoosmolality would sup-
press ADH release and prevent plasma ADH from rising.
Therefore, although an impaired ADH metabolism could play
a contributory role, the main cause of the increased plasma lev-
els of ADH in our patients was probably an increased secre-
tion of this hormone.
In the current study, as well as in previous investigations
[6—8], the role of ADH in water retention in cirrhosis is in-
ferred from the finding of an inverse relationship between
plasma ADH after water loading and free water clearance. It
is important, however, to remark that this relationship does not
necessarily mean that ADH is the only factor involved in the
impaired water excretion in these patients. In fact, Epstein et
al [19] and Reznick et al [20] have recently found in cirrhotic
patients with ascites a dissociation between the failure of ADH
plasma level to become suppressed during water immersion or
after the insertion of a LeVeen shunt and the improvement of
water excretion obtained with these procedures, suggesting
that factors other than ADH may be also of great importance
in the pathogenesis of this disorder. The results of the current
study in relation to ADH levels after water loading further sup-
port the suggestion that this hormone is not the only mecha-
nism involved in renal water metabolism in cirrhosis. The
plasma concentration of ADH after water loading in most of
our patients of group 2 was similar to that presented by nor-
mal subjects after water restriction (Fig. 3), indicating that cir-
rhotic patients are able to elaborate a hypotonic urine in spite
of having increased plasma levels of ADH.
During the last few years, evidence has been presented in-
dicating that renal prostaglandins, particularly PGE2, play a
major role in renal water metabolism. It is well established that
prostaglandins of the E series inhibit vasopressin-stimulated
water reabsorption [21, 22]. On the other hand, inhibition of
prostaglandin synthesis enhances the antidiuretic effect of
ADH [23, 241. Finally, it has been demonstrated that ADH
stimulates the renal synthesis of PGE2 [25]. These studies,
therefore, strongly support that a short loop negative feedback
exists in which ADH itself stimulates the synthesis of its an-
tagonist PGE2 in the collecting duct epithelial cells [9, 26].
The current study indicates that renal PGE2 plays an impor-
tant role in renal water metabolism in cirrhosis. Patients of
group 2 showed a significantly higher urinary excretion of
PGE2 in basal conditions (Fig. 2) and after water restriction and
water loading (Table 3) than normal subjects did. Since the uri-
nary excretion of PGE2 is considered to estimate its renal syn-
thesis [27], the most likely explanation for this finding is that
these patients had an increased renal production of PGE2.
Therefore, it could be suggested that patients of group 2 were
able to elaborate a positive free water clearance in spite of hav-
ing high plasma levels of ADH after water loading because the
hydroosmotic effect of this hormone was antagonized by an in-
creased renal synthesis of PGE2. The results of protocol 2 are
in keeping with this contention. The administration of lysine
acetylsalicylate was associated with a marked reduction of uri-
nary excretion of PGE2 in all subjects included in this proto-
col. Although in cirrhotic patients this could be partially due
to the decreased urine volume produced by the drug [28], the
observation that urine PGE2 also decreased in normal sub-
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jects, who did not develop a fall in urine volume, indicates that
lysine acetylsalicylate inhibited the renal synthesis of PGE2. In
agreement with previous reports [29, 30], prostaglandin inhi-
bition was associated with a marked impairment of renal func-
tion in many of the patients with cirrhosis and ascites studied.
Out of the 12 patients included in protocol 2, 6 developed a pro-
found and reversible reduction of GFR after lysine acetylsa-
licylate administration. However, this did not occur in the re-
maining 6 patients with ascites or in the normal subjects. Since
it has been shown in cirrhotic patients with ascites that lysine
acetylsalicylate induces parallel changes in GFR and renal
plasma flow [30], it is very likely that this drug reduced renal
plasma flow in the 6 patients who developed a decrease in GFR
but not in the remaining 6 patients. In addition to its effect on
renal hemodynamics, lysine acetylsalicylate produced a
marked reduction of free water excretion in all patients stud-
ied but not in normal subjects. Because this reduction of free
water clearance occurred in the absence of changes in plasma
ADH concentration and independently of changes in GFR, the
most likely explanation is that lysine acetylsalicylate impaired
water excretion in cirrhotic patients with ascites through an in-
hibition of prostaglandin synthesis. These findings strongly
suggest that the increased renal synthesis of PGE2 in cirrhosis,
by antagonizing the hydroosmotic effect of ADH, plays an im-
portant role in the maintenance of free water excretion in these
patients.
Patients of group 3, who were unable to elaborate a positive
free water clearance after a water load, showed a significantly
lower urinary excretion of PGE2 in basal conditions and fol-
lowing water restriction and water loading than normal sub-
jects. Because it has been demonstrated that urinary excretion
of PGE2 is flow-dependent [28], it could be suggested that the
reduced urine PGE2 was secondary to the low urine volume
presented by these patients; however, there are several rea-
sons to doubt this possibility in the present study. First, al-
though there were no significant differences between patients
of groups 2 and 3 in urine volume obtained in basal conditions
and following water restriction, marked differences were ob-
served in relation to the urinary excretion of PGE2. Second,
urinary excretion of PGE2 has been found to be flow-depen-
dent over a range of urine flow rate of 4 mi/mm or more [28],
whereas in the three groups of subjects studied the mean urine
volume in basal conditions and after water restriction ranged
between 0.37 and 0.8 mllmin. Finally, in all subjects studied
there was no correlation between urine volume and urinary ex-
cretion of PGE2 in basal conditions (r = 0.05) or after water
restriction (r = 0.04). Therefore, it is unlikely that the differ-
ences in the urinary excretion of PGE2 observed between the
three groups were due to their different urine flow rates. An-
other hypothesis that could be raised is that the low urinary ex-
cretion of PGE2 in patients of group 3 was a consequence of
their impaired GFR. However, this is also an unlikely expla-
nation because there are studies indicating that urinary PGE2
is not necessarily influenced by GFR. It has been shown that
patients with chronic renal failure have normal or increased
urinary excretion of PGE2 in spite of a marked reduction of
GFR [31, 32]. On the other hand, Dunn, Liard, and Dray [33]
and Frolich et al [271 have found in animals and in humans that
the intrarenal injection of angiotensin II increases the urinary
excretion of PGE2 in spite of a simultaneous decrease of renal
blood flow and GFR. Finally, we have observed during the ad-
ministration of demeclocycline to patients with cirrhosis and
ascites a marked increase of the urinary excretion of PGE2 in
the setting of a profound impairment of renal hemodynamics
[34]. Therefore, the most likely explanation for the reduced uri-
nary excretion of PGE2 in patients of group 3 is that it was sec-
ondary to a reduced renal synthesis of PGE2. In addition to the
low urinary PGE2, patients of group 3 showed a marked im-
pairment of renal function and very high plasma concentration
of ADH, Thus, the profound impairment of water excretion in
these patients was probably caused by the simultaneous occur-
rence of impaired renal function, reduced prostaglandin syn-
thesis, and nonosmotic hypersecretion of ADH.
The results of the current study suggesting that PGE2 plays
a major role in renal water metabolism in cirrhotic patients with
ascites may be relevant in interpreting the results of previous
investigations on ADH in these patients. As mentioned above,
Epstein et al [19] and Reznick et al [20] found that in patients
with cirrhosis and ascites the expansion of the "effective"
extracellular volume obtained during water immersion or after
the insertion of a LeVeen shunt improved water excretion
without a concomitant suppression of ADH. Because both pro-
cedures increased osmolar clearance and sodium and potas-
sium excretion, it was suggested that they improved water ex-
cretion by raising the distal delivery of filtrate. Epstein et al
have recently demonstrated that water immersion increases
PGE excretion in normal subjects [35] and cirrhotic patients
with ascites [36]. Interestingly enough, in their studies cir-
rhotic patients manifested a significantly greater augmentation
of PGE excretion than did normal subjects in spite of a similar
increase in urine volume, which suggests that immersion-in-
duced augmentation of PGE excretion in these patients could
not be solely attributable to an increase in urine flow rate but
reflected a rise in renal PGE production. Therefore, it is pos-
sible that the improvement of water excretion after the expan-
sion of "effective" extracellular volume in cirrhotic patients
with ascites is secondary not only to an increase in the distal
delivery of filtrate, but also to an increase in the renal synthe-
sis of PGE that antagonizes the tubular effect of the high
plasma levels of ADH present in these patients.
As occurred in the patients studied by Bichet et al [6, 7], in
our patients the plasma concentration of ADH correlated with
the degree of activation of the renin-angiotensin and sympa-
thetic nervous systems. Patients of group 3, who had the high-
est plasma concentration of ADH, were those who had the
highest levels of PRA and plasma concentration of NE. These
results are consistent with the hypothesis that hypersecretion
of ADH in cirrhosis is secondary to the systemic circulatory
disturbance observed in these patients [7]. Because angioten-
sin II [37], ADH [25], and the activity of the sympathetic nerv-
ous system [38] are powerful stimuli of the renal synthesis of
prostaglandins, it is likely that the increased renal production
of PGE2 in patients of group 2 was secondary to the activated
renin-angiotensin and sympathetic nervous systems and to the
high plasma levels of ADH seen in these patients. We have,
however, no clear explanation as to why patients of group 3
had an impaired renal excretion of PGE2 in spite of their hav-
ing very high plasma levels of renin, NE, and ADH. Recently,
we have measured the fatty acid composition of total plasma
lipids in 14 cirrhotic patients with ascites and 43 normal sub-
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jects by gas liquid chromatography (A. Rimola, unpublished
observations). There were no significant differences between
both groups with respect to linoleic acid (normal subjects, 24.8
1.1%; cirrhotic patients, 23.8 1.6%). But the cirrhotic pa-
tients showed a significantly lower arachidonic acid than nor-
mal (3.0 0.3% vs. 6.3 0.3%; P < 0.01). Therefore, it could
be possible that impaired renal prostaglandin synthesis in cir-
rhotic patients with negative free water clearance could be re-
lated to a reduced hepatic transformation of linoleic acid to the
prostaglandin precursor arachidonic acid. Obviously, further
studies are necessary to clarify these findings.
In conclusion, the current investigation indicates that the
pathogenesis of water retention in cirrhosis is complex and
probably multifactorial. Our results confirm previous studies
suggesting that hypersecretion of ADH and impaired renal he-
modynamics may be involved in the pathogenesis of this dis-
order. The most outstanding finding of this study was, how-
ever, that PGE2 seems to play a major role in the maintenance
of water excretion in these patients. Prostaglandin inhibitors
should be used with great caution in cirrhotic patients with as-
cites, not only because they may cause an impairment of renal
plasma flow and GFR, but also because they constantly pro-
duce a marked reduction of the renal ability to excrete free wa-
ter in these patients.
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